GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Loans Receivable

MYND Life Sciences (XCNQ:MYND) Loans Receivable : C$0.00 Mil (As of Jul. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences Loans Receivable?

MYND Life Sciences's Loans Receivable for the quarter that ended in Jul. 2024 was C$0.00 Mil.


MYND Life Sciences Loans Receivable Historical Data

The historical data trend for MYND Life Sciences's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences Loans Receivable Chart

MYND Life Sciences Annual Data
Trend Oct21 Oct22 Oct23
Loans Receivable
- - -

MYND Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MYND Life Sciences Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


MYND Life Sciences Loans Receivable Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


MYND Life Sciences Business Description

Traded in Other Exchanges
Address
105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2
MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.